Skip to content
- BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
- Scott R, Rimel BJ.
- OncLive. 2022 Nov 4.
- Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer.
- Monk BJ, Coleman RL, Westin SN, Birrer MJ.
- OncLive. Peer Exchange. 2022 Nov 4.
- Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment.
- Monk BJ, Coleman RL, Westin SN, Birrer MJ.
- OncLive. Peer Exchange. 2022 Nov 4.
- Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
- Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA.
- JCO Precis Oncol. 2022 Nov;6:e2200309. doi: 10.1200/PO.22.00309.
- Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.
- Gross M, Spencer RJ.
- Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715.